Boehringer Ingelheim Pharmaceuticals Inc. receives FDA approval for Cyltezo adalimumabadbm a biosimilar to Humira for the treatment of multiple chronic inflammatory diseases

RIDGEFIELD Conn. Aug. 29 2017 PRNewswire Boehringer Ingelheim Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration FDA approved Cyltezo a biosimilar to Humira in a prefilled syringe for the treatment of multiple chronic inflamm...